LIfT BioSciences is thrilled to announce that it has raised $12,000,000 to accelerate the development of its groundbreaking cancer treatment technology. This significant funding milestone underscores the confidence from investors in LIfT’s innovative approach to oncology, which centers around its first-in-class Immunomodulatory Alpha Neutrophils (IMANs). By harnessing the power of the body’s natural immune defenses, IMANs not only attack tumours directly but also reprogram the tumour microenvironment to rally the immune system for a more robust and sustained anti-tumour response. Leveraging the patented N-LIfT platform—developed through a state-of-the-art process involving exceptional stem cells (iPSC or HSC), proprietary enhancement media, and genetic engineering techniques such as CARs—the company is poised to deliver CAR-IMAN cells that potentially multiply a patient’s inherent cancer-killing capabilities by hundreds of times.
This investment is set to support LIfT BioSciences’ ambitious plans to launch a Series A proof-of-concept clinical trial, moving a step closer to commercialisation. The funds will facilitate crucial lab work, regulatory preparations, and early-phase clinical investigations, paving the way for partnerships with pharmaceutical license partners focused on co-developing therapies that aim to achieve complete remission in patients with solid tumours. Founded by Alex Blyth, whose personal loss to pancreatic cancer fuels his commitment to transforming cancer treatment, LIfT BioSciences is uniquely driven by both innovation and passion. As discussions continue with syndicate and co-development partners, the company remains steadfast in its vision to create durable responses and lasting immunity for cancer patients, potentially revolutionising the treatment landscape before the decade is out. For more details, visit www.liftbiosciences.com.
.png&w=3840&q=75)
